Back
Real-World Evidence on the Efficacy and Durability of Novel Therapies for nAMD, DME, and RVO
Retina specialists come together to share key insights from multiple patient cases, highlighting how novel therapies like faricimab and aflibercept 8 mg have improved durability and patient outcomes in neovascular AMD, DME, and RVO.
Real-World Evidence on the Efficacy and Durability of Novel Therapies for nAMD, DME, and RVO
Episodes
All
All
Advertisement
Advertisement
Trending on HCPLive
1
Tirzepatide Demonstrates Cardioprotective Effects in T2D With ASCVD
2
Phase 3 Dermatomyositis Trial Sees Brepocitinib Meet Primary Endpoint
3
Q&A: Fear, Not Appetite Loss, Drives ARFID Eating Patterns in Food Allergy
4
European Society of Cardiology 2026 Preview: 6 Trials to Know
5